News Article | November 8, 2016
SÃO PAULO, Brasil & TEL AVIV, Israel--(BUSINESS WIRE)--MyHeritage, o destino internacional número um para se descobrir, preservar e compartilhar a história da família, anunciou hoje o lançamento do MyHeritage DNA – seu serviço global de teste genético. Este passo representa uma reviravolta na indústria do DNA, já que o MyHeritage DNA entra no mercado de kits de testes domésticos com um produto simples de usar, com preço bastante acessível e que irá apresentar uns dos melhores relatórios de etnicidade do planeta. Com 85 milhões de usuários no mundo todo, 2,1 bilhões de perfis em árvores genealógicas, 7 bilhões de registros históricos e disponível em 42 idiomas, o novo serviço de DNA do MyHeritage consolida sua posição como líder global na genealogia. DNA é o material hereditário presente nas células do corpo humano, que carrega um registro histórico único. O kit para DNA do MyHeritage permite que os usuários testem seu DNA, para revelar informações pertinentes em relação à sua história familiar e origem étnica. O kit consiste de um simples cotonete para a bochecha e só leva um minuto para ser usado – não sendo necessário coletar sangue ou saliva. A amostra recolhida é então enviada para análise, através do correio, para o laboratório do MyHeritage DNA e o usuário é convidado a visualizar os resultados no site do MyHeritage. Na sua versão inicial, o MyHeritage DNA dispõe de duas funções principais: relatórios étnicos detalhados que fazem o mapeamento da origem étnica e geográfica do usuário, além de matches de DNA para que parentes sejam encontrados. Funções adicionais estão planejadas para o futuro. Os resultados do MyHeritage DNA incluem relatórios étnicos fascinantes, em que é exibida qual percentagem do DNA do usuário é originária de quais populações do mundo. Os relatórios iniciais contemplam atualmente 25 etnias, mas este resultado irá aumentar dramaticamente graças a um plano exclusivo do MyHeritage com o projeto de população fundadora revelado hoje – o maior projeto do tipo jamais conduzido. Mais de cinco mil participantes foram escolhidos pelo MyHeritage para participar deste projeto, dentro de um pool de 85 milhões de membros, tendo como base a árvore genealógica de cada usuário – que mostra antepassados pertencentes a um determinado grupo étnico, ou região, por várias gerações. Nos próximos meses, este projeto será concluído e terá como resultado um rico conjunto de dados de DNA de mais de 100 etnias. Com isso, o MyHeritage poderá mostrar para os seus usuários as suas raízes ancestrais, provenientes de mais de 100 etnias diferentes, com muito mais precisão que outros serviços de DNA. Com isto em mente, a empresa começou a enviar seus kits de DNA para participantes do projeto, espalhados por todo o planeta, do Uzbequistão às Ilhas Fiji, da Groenlândia até a África do Sul, chegando a todos os cantos da Terra. Os relatórios étnicos padrão já estão à disposição, e os relatórios avançados serão oferecidos aos usuários sem nenhum custo adicional, assim que o projeto da população fundadora tiver sido concluído. Os resultados dos testes de DNA vêm complementar os serviços principais do MyHeritage – as árvores genealógicas e registros históricos, ambos instrumentos usados tradicionalmente por entusiastas da história familiar. O DNA pode ser usado para provar ou refutar uma conexão documentada na árvore genealógica, ou para responder à pergunta se duas pessoas que compartilham o mesmo e incomum sobrenome são realmente parentes. O DNA também é indispensável para se transpor barreiras insuperáveis da genealogia tradicional, como no caso de pessoas adotadas que querem buscar seus parentes biológicos, sem nenhum acesso aos registros de adoção. Por outro lado, quando o DNA localiza matches entre dois indivíduos, que têm o mesmo antepassado, ou antepassados, as árvores genealógicas e registros históricos são muitas vezes essenciais, para se juntar o quebra-cabeça e verificar qual é o grau de parentesco exato entre os dois. O MyHeritage DNA está integrado aos outros serviços oferecidos pelas plataformas web e móvel do MyHeritage, bem como num aplicativo móvel independente lançado hoje e denominado MyHeritage DNA. Graças à experiência com árvores genealógicas e a sua comunidade multicultural, o MyHeritage pode oferecer aos seus clientes interessados em DNA funções não contempladas por serviços concorrentes, como o 23andMe, incluindo a visualização de árvores genealógicas juntamente com a maioria dos matches de DNA, bem como a identificação automática de quais sobrenomes e localizações geográficas são compartilhadas. O DNA pode ser uma porta de entrada fascinante para o mundo da genealogia e clientes que embarcarem nesta jornada através de testes de DNA podem facilmente passar a usar as ferramentas de MyHeritage para explorar ainda mais os caminhos que os fizeram chegar até aqui. Os kits de DNA do MyHeritage estão disponíveis por um preço inicial bastante acessível de apenas US$79 + correio (preços variam de acordo com a localização). Para pedir um kit, basta visitar o site de DNA do MyHeritage. O MyHeritage já acumulou um número significativo de kits, disponibilizados por seus usuários, que fizeram seus testes com vários provedores diferentes, de forma que os matches importantes já estão sendo calculadas desde o primeiro dia. Com o lançamento do MyHeritage DNA, a empresa irá parar de disponibilizar kits de outros provedores. Os usuários que já fizeram seus testes com outras empresas poderão fazer o upload de seus resultados no site do MyHeritage gratuitamente, por um tempo limitado, para poderem se beneficiar das coincidências de DNA.
News Article | March 1, 2017
Globally the market for pharmacogenomics is increasing rapidly mainly due to increasing safety in drug. The factors that influence the growth of Pharmacogenomics market; rising utilization in medication revelation processes, increasing interest for customized drugs, expanding security in treatment, Improve evidence of guideline for adequacy trials. • Myriad Genetics, Inc (U.S) • Transgenomic, Inc(U.S) • 23andMe (U.S) • Pathway Genomics (CA) • Genetech (CA) • GeneDX (U.S) • Teva Pharmaceutical Industries Ltd.(Israel) • Illumina, Inc.(U.s) • Assurex Health, Inc.(U.s) The report for Pharmacogenomics of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The market for pharmacogenomics is segmented into mainly three; by application, by therapeutic application, by end user and its various sub-segments. By application include drug safety, Tailor treatments, drug discovery and others. Whereas by therapeutic application include cancer, oncology, cardiovascular and others. Furthermore by methods include haplotype analysis, multivariate techniques, quantitative trait analysis and others. Taste the market data and market information presented through more than 50 market data tables and figures spread in 120 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Pharmacogenomics Market Research Report - Forecast to 2027” • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the global pharmacogenomics market • To provide insights about factors affecting the market growth • To Analyze the Pharmacogenomics Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segment by application, by therapeutic application, by methods and its sub-segments. • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global pharmacogenomics market. Americas • North America • US • Canada • Latin America Europe • Western Europe • Germany • France • Italy • Spain • UK • Rest of Western Europe • Eastern Europe Asia– Pacific Asia • China • India • Japan • South Korea • Rest of Asia Pacific The Middle East& Africa The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. Global Infusion Systems market, by Product Type (Ambulatory Pumps, I.V. Disposables, Syringe Pump Systems, Volumetric Pump Sets and others), by applications (chemotherapy, cardiovascular diseases, Diabetes, Pediatrics and others) by end users (Hospitals, Clinics, Research Laboratories and others) - Forecast to 2027 https://www.marketresearchfuture.com/reports/infusion-systems-market At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com/reports/pharmacogenomics-market
News Article | February 22, 2017
NEW YORK--(BUSINESS WIRE)--Celmatix, a next-generation women’s health company, and 23andMe, the leading personal genetics company, today announced the launch of a new fertility research community. The goal of this initiative is to recruit 4,500 women, aged 18-45, who are trying to conceive or who have recently conceived. In addition to collecting genetic data from participants, the study will longitudinally track clinical, environmental, lifestyle, diet-associated, and fertility outcome metrics. This dataset will contribute to Celmatix’s larger research efforts, which are aimed at understanding factors that contribute to lifelong reproductive potential in a diverse population with the aim of identifying new genetic and other markers related to reproductive health. Women aged 18-45 who are trying to conceive or who have recently conceived can participate from home by consenting to provide a DNA sample (saliva), answering online surveys (one every two months for 18 months), and agreeing to share their de-identified, individual-level data with researchers. All study participants will receive 23andMe’s Personal Genome Service® at no cost. The study is currently open to U.S. residents only. “ Celmatix was founded with the goal of empowering women to be more proactive in managing their reproductive health through better data, including genetics,“ explained Celmatix founder and CEO, Dr. Piraye Yurttas Beim. “23andMe is the ideal collaborator to help recruit and manage this fertility research community given their shared vision for enabling people to be more proactive about their health through genetic insights and, also, the passion of their customer base for contributing to groundbreaking research. This ambitious initiative will bring us closer to enabling any woman, who may want to have a child one day, better understand how decisions about lifestyle, diet, and when to start building a family may impact her ability to have as many children as she wants given her underlying genetics. Many studies have explored these factors in isolation. This is the first study to bring them all together in one longitudinal dataset.” “ Many women struggle with fertility challenges, and yet there's still a limited understanding about what causes differences in fertility. For women who have faced difficulties when trying to conceive, there is the desire to understand why this is happening. And for women entering their child-bearing years, it can be frustrating to realize there are significant unknowns about one's fertility that can have big implications. Ultimately, this study has the capability to positively impact our understanding of fertility by leveraging big data, helping women understand their unique fertility, and empowering potential parents to make informed choices," explained Emily Drabant Conley, PhD, vice president of business development from 23andMe. Dr. Jorge E. Chavarro, MD, from the Harvard T.H. Chan School of Public Health, and a scientific advisor to the study, stated, “ The studies we have available right now to counsel women on their reproductive potential don’t include genetic-level insight and are generally smaller and less detailed than studies in other areas of health. A landmark study of this kind that simultaneously tracks the impact of environment, diet, lifestyle, and clinical metrics in the context of genetic background, on fertility potential and outcomes has never been conducted on this scale. Not only does this work have the potential to drive the next generation of personalized medicine products to impact clinical management, but it will also likely result in significant contributions to our fundamental understanding of the science of fertility.” To learn more about the study, please visit www.23andme.com/fertility. Celmatix is a next-generation women’s health company transforming reproductive health care through genomics and big data. Founded in 2009 and based in New York City, Celmatix is disrupting how women approach their lifelong fertility journey by empowering them with more personalized information. The company’s research-driven products include Fertilome®, the world’s first multigene panel test that reveals what a woman's DNA says about her reproductive health, and Polaris®, a real-time predictive analytics platform in use at leading fertility clinics across the U.S., which helps physicians optimize patient outcomes and improve the patient experience. For more information, visit www.celmatix.com. 23andMe, Inc. is the leading personal genetics company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. 23andMe has over one million customers worldwide with over 80 percent consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at www.23andMe.com.
News Article | September 7, 2016
Misha Angrist is not worried about strangers discovering his personal genetic information, even though it was made public in 2007 and has his name attached. Angrist was the fourth person to submit his genetic sequence to the Personal Genome Project, an effort led by George Church, a geneticist at Harvard Medical School in Boston, Massachusetts, to advance medicine by publicly sharing genomic and health data. “It was kind of a political statement,” says Angrist, a geneticist who studies bioethics and science policy at Duke University's Social Science Research Institute in Durham, North Carolina. He had become frustrated that privacy considerations prohibited scientists involved in genetic studies from interacting with the people those genes belonged to. “We were not allowed to talk to the people we studied, and that always struck me as silly and wrong-headed,” he says. The restrictions prevented researchers from gathering additional information, such as recent medical histories or health-related habits, that might give them more insight into disease risk — and stopped them developing a trusting relationship with the DNA donors. The Personal Genome Project aims to share DNA sequences, medical histories and other personal information with researchers looking to link gene variants, environment and lifestyle habits to disease risk. The project explicitly does not promise anonymity, and warns that the data will be shared publicly. Each participant is put through an online, questionnaire-based screening process to ensure that they understand both the benefits and the risks of making such information available. The US Precision Medicine Initiative, meanwhile, is seeking to collect the genomic information and medical records of 1 million participants, and the UK 100,000 Genomes Project is gathering similar data through the National Health Service, raising concerns among privacy advocates that too much personal information could become public. Both projects promise to remove information that identifies participants from the data, and store the data on secure servers that are accessible only to authorized personnel, and they prohibit people from re-identifying the sequences. They concede, however, that anonymity cannot be absolutely guaranteed, and computer scientists have shown that at least some participants can be re-identified fairly easily. Scientists and policymakers are trying to work out exactly what the harm of such disclosures could be, and how they can reduce the risks, but any solutions are more likely to be policy-based than technological. Anonymous data are not as unidentifiable as the term suggests. Not all participants in the Personal Genome Project are identified by name like Angrist, but the project does not guarantee anonymity. In 2013, Latanya Sweeney, a computer scientist who heads Harvard's Data Privacy Lab, was able to put names to many of the profiles simply by comparing them with available public records. More than half of the nameless profiles available at the time contained the person's date of birth, gender and postal zip code. By cross-checking against public records such as voter registrations, she was able to attach a name and address to 241 of the 579 profiles. Staff at the Personal Genome Project confirmed that she was correct in all but 7 cases. The Personal Genome Project is not the only database that is vulnerable to re-identification. Yaniv Erlich, a computer scientist at Columbia University in New York City looked at repeating patterns of nucleotides, known as short tandem repeats (STRs), on the Y chromosomes of men whose DNA had been made publicly available by the international 1000 Genomes Project. He then compared them with data found on two public genealogy databases. The project had not collected names or other identifying information, such as birth date or social security number, and because it stored more samples than were used, there was no way to tell if a given sample was even part of the database. As the project's consent form reassuringly put it: “Because of these measures, it will be very hard for anyone who looks at any of the scientific databases to know which information came from you, or even that any information in the scientific databases came from you.” Despite that promise, however, Erlich was able to put names to nearly 50 people who had donated their DNA. Because the Y chromosome is inherited only by males, it is often linked to family surnames. This means that even if participants in the genome study had not also given their DNA to a genealogy website, people with matching STRs were probably relatives, allowing the researchers to infer more surnames. When his study was published in 2013, Erlich estimated that 12% of US males were vulnerable to this kind of breach. Three years later, with genome databases growing and algorithms for comparing data improving, that figure could be as high as 20%. “It definitely gets easier and easier,” he says. “With some knowledge and some dedicated effort, you can identify people from genomic data.” Even those who agree to make their data public may have some information that they would rather keep from other people — or even from themselves. One participant in the Public Genome Project was James Watson, co-discoverer of the double helix structure of DNA. Watson asked that information about his apolipoprotein E gene be redacted — a variant of that gene can indicate a heightened risk for developing Alzheimer's disease, and he did not want to know his risk. But researchers from the Queensland Institute of Medical Research in Australia and the University of Washington School of Medicine pointed out that merely removing the gene from the database would not hide the information. Other changes to the genome, some in fairly distant parts of the DNA, are correlated with the higher-risk mutation. Watson responded by deleting an even larger swathe of his genome from the database. But that could be a losing battle, the researchers warned. As our understanding of the genome improves, it will be easier to estimate risks for various diseases from different points along the genome. If privacy cannot be guaranteed, the next question is whether this is a problem. Some risks seem relatively minor, such as the potential embarrassment of having people find out that you participated in a particular study. But some adoptees have used genetic data to find birth parents who had not expected their identity to be revealed. Others might discover that someone they thought to be a parent or grandparent is not actually related to them. Include someone's medical history and the potential for awkward revelations grows. If a name can be attached to a genome, and the genome is attached to medical records, then treatments for sexually transmitted diseases, alcoholism or mental illness could be revealed. Some people worry that they may face job discrimination — or health-insurance discrimination in the United States — if a risk of debilitating and expensive diseases is made public. Some privacy advocates worry that despite the general guidelines developed for the Precision Medicine Initiative, the project lacks legal protections. The World Privacy Forum, a non-profit organization based in San Diego, California, says that data collected by the project are not covered by the main US health-privacy law, the Health Insurance Portability and Accountability Act of 1996. It also fears that courts may decide that when participants volunteer information to researchers, they give away their right to doctor–patient confidentiality. Courts have, after all, previously ruled that police do not need a warrant to collect mobile-phone location data because callers have already shared that information with telephone companies. “People are still worried about discrimination in health insurance and jobs,” says Robert Cook-Deegan, a biologist who studies genomics policy at Duke University's Sanford School of Public Policy. In the United States, the Genetic Information Nondiscrimination Act of 2008 is supposed to prohibit that, but it does not cover long-term care or disability insurance, so people who discover that they may need extensive care for a late-onset disease such as Alzheimer's could still face ruinous expenses. The Canadian government recently debated a similar law, and the European Union has a general mandate against genetic discrimination. There is no specific UK law against it, however, although the Association of British Insurers agreed to a moratorium until 2019 on using predictive genetic tests to inform insurance policies. Some of the concerns are speculative, such as the possibility that someone's DNA could be planted at a crime scene. Indeed, the trouble with figuring out how to handle privacy, Erlich says, is that “we really don't understand the concept of harm due to privacy loss.” If anything, the risk of personal information being revealed is probably no greater than that from other sources where people willingly provide information, Erlich says. He points to a 2013 study by researchers at the University of Cambridge, UK, and Microsoft Research that identified people's sexual orientation, political affiliation and race with high degrees of accuracy just by examining their 'likes' on Facebook. That is much more information than you could glean from a genome at present. “There is not a single genetic marker in the genome that can predict homosexuality,” Erlich says. Privacy may not even be the right focus, argues Jenny Reardon, a sociologist at the Center for Biomolecular Science and Engineering at the University of California, Santa Cruz, who in May chaired a conference focusing on the fraught issue of personal data in the age of precision medicine. “Privacy doesn't get us to what is more fundamental: what as a society should we be doing with this data,” she says. She would like to see more focus on how these large data sets can improve people's lives. But “no one wants to discuss this”, she says. Whatever the problem with privacy, the solution is unlikely to be technological, Erlich says. Techniques to encrypt data or disguise it with statistical noise are of limited value, he explains, because the more they protect privacy, the less useful they make the data. He thinks that a better approach is to rethink how privacy and consent are handled, and to treat the people who hand over their DNA with respect and honesty. In an example of this approach, Erlich and colleagues at the New York Genome Center, in collaboration with the National Breast Cancer Coalition in Washington DC, have created a project called DNALand to study the genetic risks of breast cancer. People donate the genetic information that they get from DNA-testing companies such as 23andMe, Family Tree DNA and Ancestry.com. In return, DNALand offers users free information about their genome and the possibility of identifying relatives based on genetic matches, as well as the chance to contribute to improving medical knowledge. The consent form spells out the risks and benefits of participating and allows people to withdraw at any time. It also promises to seek further consent before sharing data with a third party. One problem in obtaining consent is that, once collected, genomic data can be stored indefinitely and used in ways that the original researchers did not foresee. “That's the whole idea of research. You don't know what you're going to find,” Cook-Deegan says. The people who set up databases need to take a long view when making promises and asking for consent as they collect the data, he says. The Precision Medicine Initiative has a set of general guidelines about transparency and respect for participants' wishes, and these will be used to inform the future development of more concrete privacy protocols. “The problem we're going to have is to make sure we have a system that respects the rights and interests that were set up at the front end,” Cook-Deegan says. Not being clear about how participation in a study could lead to privacy breaches creates the risk that any problems that arise may make potential donors less willing to have their DNA sequenced. “We can't do research on human beings and look people in the eye and promise them that nothing bad will ever happen,” Angrist says. “If we reassure people and something bad happens, then it's that much worse.” Instead, he argues, engaging with donors and spelling out the risks and benefits can change the privacy equation. “If you talk to people who have children with undiagnosed diseases, they would tell you: 'We would gladly forgo privacy in the interest of accelerated research'.”
News Article | February 16, 2017
Paris, le 16 février 2017 - Capgemini, l'un des leaders mondiaux du conseil, des services informatiques et de l'infogérance, annonce l'acquisition d'Idean, société en forte croissance de conseil en stratégie digitale et en « experience design ». Basée à Palo Alto, elle dispose également de « studios » à Austin, Los Angeles, New York, San Francisco, Helsinki et Berlin. Idean renforcera la gamme de services digitaux de Capgemini en « experience design » et en stratégie, particulièrement dans la région Amérique du Nord, ainsi que son réseau de studios digitaux. Le Groupe est ainsi en mesure de répondre à la demande croissante des clients pour des services digitaux de bout en bout. « En matière de stratégie digitale, la demande des clients évolue ; ils sont à la recherche de design, de créativité et d'agilité pour repenser intégralement l'expérience client. Ce sont ces critères qui font aujourd'hui la différence dans le choix d'un partenaire digital et qui constituent la base d'un véritable dialogue stratégique avec nos clients. L'acquisition d'Idean s'inscrit dans la stratégie de croissance du Groupe axée sur l'innovation et le digital, particulièrement en Amérique du Nord », explique Paul Hermelin, Président-directeur général du groupe Capgemini. « En alliant une culture scandinave du design à une sensibilité technologique inhérente à sa situation dans la Silicon Valley, Idean s'intègre parfaitement à notre offre de services en Digital Customer Experience et la renforce. » Fondée à Helsinki en Finlande en 1999, Idean est spécialisée en « digital user experience » (UX), « customer experience » (CX) et stratégie digitale. Forte de 18 ans d'expertise, Idean compte aujourd'hui plus de 150 collaborateurs - digital strategists, experience designers et développeurs front-end - au service d'un large portefeuille de clients basés aux Etats-Unis et en Europe : start-ups de la baie de San Francisco, géants des technologies - dont beaucoup sont basés sur la côte Ouest des Etats-Unis, grandes marques des secteurs de l'automobile ou des biens électroniques, et entreprises de tous horizons en pleine transformation digitale. Idean compte parmi ses références : LG, Mercedes-Benz, Sony, Volkswagen, 23andMe, Airbus, Cole Haan, Ericsson, IBM, Intel, Kesko. A partir d'une compréhension complète des problématiques des utilisateurs, Idean accompagne ses clients dans trois domaines : la détection d'opportunités stratégiques ; la conception et la création d'expériences digitales ; et enfin l'évolution de leurs méthodes de travail, notamment le design thinking. « Nous avons fondé Idean afin d'aider les entreprises à identifier de nouvelles opportunités stratégiques et à créer des expériences digitales fondées sur une compréhension parfaite du comportement de leurs utilisateurs », ajoute Risto Lahdesmaki, Président-directeur général et fondateur d'Idean, qui va rejoindre Capgemini. « Nous sommes ravis de rejoindre Capgemini : c'est un nouveau chapitre prometteur qui s'ouvre. Nos clients pourront immédiatement bénéficier d'une gamme étendue de services en stratégie digitale et transformation de l'expérience client ainsi que d'une expertise pointue en matière de véhicules connectés et d'Internet des Objets, et ce à l'échelle mondiale. Rejoindre Capgemini offrira également à nos collaborateurs l'opportunité de travailler sur de nouveaux projets et auprès de nouveaux clients, ainsi que de nouvelles perspectives de carrière. » À propos de Capgemini Avec plus de 190 000 collaborateurs, Capgemini est présent dans plus de 40 pays et célèbre son cinquantième anniversaire en 2017. Le Groupe est l'un des leaders mondiaux du conseil, des services informatiques et de l'infogérance et a réalisé en 2016 un chiffre d'affaires de 12,5 milliards d'euros. Avec ses clients, Capgemini conçoit et met en oeuvre les solutions business, technologiques et digitales qui correspondent à leurs besoins et leur apportent innovation et compétitivité. Profondément multiculturel, Capgemini revendique un style de travail qui lui est propre, la « Collaborative Business ExperienceTM », et s'appuie sur un mode de production mondialisé, le « Rightshore® ». Plus d'informations sur : www.capgemini.com
News Article | February 17, 2017
PARIS, 17-Feb-2017 — /EuropaWire/ — Capgemini, a global leader in consulting, technology and outsourcing services, announced today the acquisition of Idean, a fast-growing digital strategy and experience design consultancy, headquartered in Palo Alto, with additional studios in Austin, Los Angeles, New York, San Francisco, Helsinki and Berlin. Idean will reinforce the Group’s user-centered and digital-first experience design and strategy services, particularly in North America, and extend its network of Digital studios; helping to meet growing customer demand for the Group’s end to end digital services. “Customer demand is shifting; service providers who bring digital design, creativity, and agility to redefine the customer experience are developing a strategic dialog with their clients, driving uniquely differentiated outcomes, and gaining market share as true digital partners. The acquisition of Idean is part of the Group’s growth strategy focused on innovation and digital particularly in North America,” comments Paul Hermelin, Chairman and Chief Executive Officer, Capgemini Group. “Idean’s Scandinavian design ethos and Silicon Valley mindset are a perfect fit to further enhance Capgemini’s progressive digital customer experience offerings.” Founded in Helsinki, Finland, in 1999, Idean focuses primarily on digital user experience (UX), customer experience (CX), and digital strategy. Over the last eighteen years its team of now 150+ digital strategists, experience designers and front-end developers have been working for a wide array of US and European clients, including disruptive Bay Area start-ups, global tech leaders many of whom are west coast based, prominent brands in automotive and consumer electronics, and companies reinventing themselves for the digital era; clients include LG, Mercedes-Benz, Sony, Volkswagen, 23andMe, Airbus, Cole Haan, Ericsson, IBM, Intel, and Kesko. Starting from a deep understanding of users, Idean engages with clients in three main areas: envisioning strategic opportunities, designing and building digital experiences, and changing cultures by developing competencies in new ways of working and design thinking. “We formed Idean to help organizations identify new strategic opportunities and create digital design experiences that were based on a deep understanding of their users,” explains Risto Lahdesmaki, CEO and Founder of Idean, who will join Capgemini. “Joining forces with Capgemini is extremely exciting and the logical next step of our journey. Idean clients will immediately benefit from an expanded and extensive portfolio of services for digital strategy and CX transformation, deep industry expertise in connected vehicles and IoT, and global end-to-end delivery. For our people, joining Capgemini will also open up new opportunities, from working on new clients and new projects with Capgemini teams, to expanded career prospects.” This transaction is expected to close by the end of February 2017. About Capgemini With more than 190,000 people, Capgemini is present in over 40 countries and celebrates its 50th Anniversary year in 2017. A global leader in consulting, technology and outsourcing services, the Group reported 2016 global revenues of EUR 12.5 billion. Together with its clients, Capgemini creates and delivers business, technology and digital solutions that fit their needs, enabling them to achieve innovation and competitiveness. A deeply multicultural organization, Capgemini has developed its own way of working, the Collaborative Business ExperienceTM, and draws on Rightshore®, its worldwide delivery model. Learn more about us at www.capgemini.com.
News Article | February 16, 2017
Capgemini strengthens its digital leadership with the acquisition of digital strategy and design consultancy Idean Paris, February 16, 2017 - Capgemini, a global leader in consulting, technology and outsourcing services, announced today the acquisition of Idean, a fast-growing digital strategy and experience design consultancy, headquartered in Palo Alto, with additional studios in Austin, Los Angeles, New York, San Francisco, Helsinki and Berlin. Idean will reinforce the Group's user-centered and digital-first experience design and strategy services, particularly in North America, and extend its network of Digital studios; helping to meet growing customer demand for the Group's end to end digital services. "Customer demand is shifting; service providers who bring digital design, creativity, and agility to redefine the customer experience are developing a strategic dialog with their clients, driving uniquely differentiated outcomes, and gaining market share as true digital partners. The acquisition of Idean is part of the Group's growth strategy focused on innovation and digital particularly in North America," comments Paul Hermelin, Chairman and Chief Executive Officer, Capgemini Group. "Idean's Scandinavian design ethos and Silicon Valley mindset are a perfect fit to further enhance Capgemini's progressive digital customer experience offerings." Founded in Helsinki, Finland, in 1999, Idean focuses primarily on digital user experience (UX), customer experience (CX), and digital strategy. Over the last eighteen years its team of now 150+ digital strategists, experience designers and front-end developers have been working for a wide array of US and European clients, including disruptive Bay Area start-ups, global tech leaders many of whom are west coast based, prominent brands in automotive and consumer electronics, and companies reinventing themselves for the digital era; clients include LG, Mercedes-Benz, Sony, Volkswagen, 23andMe, Airbus, Cole Haan, Ericsson, IBM, Intel, and Kesko. Starting from a deep understanding of users, Idean engages with clients in three main areas: envisioning strategic opportunities, designing and building digital experiences, and changing cultures by developing competencies in new ways of working and design thinking. "We formed Idean to help organizations identify new strategic opportunities and create digital design experiences that were based on a deep understanding of their users," explains Risto Lahdesmaki, CEO and Founder of Idean, who will join Capgemini. "Joining forces with Capgemini is extremely exciting and the logical next step of our journey. Idean clients will immediately benefit from an expanded and extensive portfolio of services for digital strategy and CX transformation, deep industry expertise in connected vehicles and IoT, and global end-to-end delivery. For our people, joining Capgemini will also open up new opportunities, from working on new clients and new projects with Capgemini teams, to expanded career prospects." This transaction is expected to close by the end of February 2017. About Capgemini With more than 190,000 people, Capgemini is present in over 40 countries and celebrates its 50th Anniversary year in 2017. A global leader in consulting, technology and outsourcing services, the Group reported 2016 global revenues of EUR 12.5 billion. Together with its clients, Capgemini creates and delivers business, technology and digital solutions that fit their needs, enabling them to achieve innovation and competitiveness. A deeply multicultural organization, Capgemini has developed its own way of working, the Collaborative Business ExperienceTM, and draws on Rightshore®, its worldwide delivery model. Learn more about us at www.capgemini.com.
PLoS genetics | Year: 2010
Despite the recent rapid growth in genome-wide data, much of human variation remains entirely unexplained. A significant challenge in the pursuit of the genetic basis for variation in common human traits is the efficient, coordinated collection of genotype and phenotype data. We have developed a novel research framework that facilitates the parallel study of a wide assortment of traits within a single cohort. The approach takes advantage of the interactivity of the Web both to gather data and to present genetic information to research participants, while taking care to correct for the population structure inherent to this study design. Here we report initial results from a participant-driven study of 22 traits. Replications of associations (in the genes OCA2, HERC2, SLC45A2, SLC24A4, IRF4, TYR, TYRP1, ASIP, and MC1R) for hair color, eye color, and freckling validate the Web-based, self-reporting paradigm. The identification of novel associations for hair morphology (rs17646946, near TCHH; rs7349332, near WNT10A; and rs1556547, near OFCC1), freckling (rs2153271, in BNC2), the ability to smell the methanethiol produced after eating asparagus (rs4481887, near OR2M7), and photic sneeze reflex (rs10427255, near ZEB2, and rs11856995, near NR2F2) illustrates the power of the approach.
News Article | December 23, 2016
Writing that out still feels strange to me, in part because I have only been able to do it for about a week now. I practiced for years in my head, of course, rolled those words around like worry stones. You don’t get a diagnosis like CF after almost 33 years in the dark without some pretty serious clues early on about what you’ve been living with. You also don’t usually get a diagnosis like CF after almost 33 years, period. Every time I tell someone about my diagnosis, I get the same question: “Aren’t people with CF usually diagnosed when they’re very young?” Yes…and no. Some of us fall through the cracks of health systems ill equipped to deal with people whose diseases present in even slightly atypical ways. And some of us never make it out of childhood. I almost didn’t. The average life expectancy for adults with CF in the United States is currently 37 years. The list of things that have almost killed me is long and detailed at this point, and I’m still four years shy of that mark. CF is a genetically inherited disease that affects the entire body. It’s often stereotyped as a lung condition, but this is a misnomer. What actually happens when you have CF is that your mucous membranes don’t work the way other people’s do. Instead of producing relatively fluid mucus that effectively lubricates your tissue and generally helps your body to function, they instead produce a sticky substance best compared to rubber cement. This sticky mucus plugs up ducts in places like the kidneys, liver, and pancreas. It traps bacteria and when those bacteria multiply, they attack and destroy the surrounding tissue, which becomes inflamed and scarred with progressively greater severity in the absence of effective treatment. Over time, the function of different organs gets more and more disrupted. Because of the ways in which it leads the body to attack its own tissue, CF may qualify as a form of autoimmune disease. This is currently debated in the literature, with a focus on whether autoimmunity is primary or secondary to the disease. Autoimmune conditions like reactive airways disease, interstitial cystitis, microscopic colitis, and Sjogren’s syndrome often occur in people with CF. I’ve been diagnosed with all of these and more in the past. Whether they are direct components of the CF syndrome as a whole or consequences of it remains unknown. But knowing I have CF certainly helps to explain why my diagnostic surgeries have always shown a certain baseline level of inflammation even after long periods of avoiding allergic triggers. What this looks like on a daily basis for me is that my entire GI tract functions poorly even with medication management, and my lungs require daily inhalations of corticosteroids to remain relatively infection-free. All of my mucous membranes are very scarred, and I have had surgery to remove severe scarring from my bladder that was pressing on the nerves and causing agonizing pain. I have also had multiple surgeries to rebuild my gums using connective tissue from the roof of my mouth. My heart is badly damaged from years of unmanaged electrolyte wasting, causing chronic long QT syndrome. Blood vessels everywhere and nerves in my hands and feet are damaged. My kidneys are showing signs of strain, but at least now I know why my urine is full of rubbery white clumps. Damage, damage, damage. I have been hospitalized several times, including a stay in the cardiac ICU. My care has been expensive, fragmented, and often totally ineffective. And yet sometimes the worst costs of all are the intangible ones, the fear and the anger and the loss. Life with CF is a constant state of uncertainty even when you know you have it. Sometimes infection hits like a train and we scramble to recover. Sometimes we drift in and out of hospitals. Sometimes we receive organ transplants. Sometimes we have other types of surgery to salvage damaged tissue. Sometimes medication helps us. Sometimes we just get lucky. Sometimes we get diagnosed early and conclusively and sometimes we wander for years. Sometimes we are told we probably won’t survive. I’ve had a mixture of all of the above experiences except organ transplantation. That may yet be on the list depending on what my next round of kidney testing shows, though I’m loath to even consider the idea of accepting an organ from a living donor. I say I’ll cross that bridge when I come to it. If having a future means doing nightly home dialysis, I’ll take it in stride. At the end of the day, the relief of knowing feels exponentially better than the fear of wondering. So why did I not know for so long? I grew up at a medical school, the child of two developmental neurobiologists whose passion for research and education was exceeded only by their love for me. My parents put an astronomical amount of effort into arguing with doctors who dismissed their concerns that I had CF. Years later, these concerns would come full circle and I would see their faces darken with remembered anger. I would feel the heavy silence in the room when my mother shared her genetic testing results with me, having taken the plunge and submitted a 23andMe test kit because she knew it could help me to know what her genome looked like. I should mention at this point that I am donor conceived. My parents have always been my parents, but I am not a direct genetic relative of my father. Because I was conceived in early 1983, before the laws about sperm donation records were changed so that families could get medical information about anonymous donors, we never knew until that moment that my CF must have come from the donor’s side. I watched my mother’s face as we reviewed her results, which showed no copies of any of the nearly three dozen gene variants associated with CF. This brings me to the second question I get asked: “Can’t you only have CF if you have matched copies of at least one variant?” The answer, at least according to more recent clinical literature, is a resounding no. Scholars first raised the possibility that heterozygous people could also present with CF as early as 1990, but it took nearly 25 years for the field as a whole to catch up. I am now paying for every one of those 25 years. The effort to recognize heterozygous forms of CF was driven largely by clinicians who noticed that many people with inconclusive results on the old “gold standard” detection method for CF—a sweat conductivity test—actually had fairly textbook symptoms. This has been the case with me. I have severe involvement of all organs potentially affected by CF except for the pancreas and liver, at least so far. Indeed, a history of inconclusive sweat tests and minimal pancreatic involvement are both common in people with both late-diagnosed CF and heterozygous CF. Another common thread in late-diagnosed CF is somewhat better long-term survival, although any epidemiologist worth their salt would tell you that’s mostly a selection effect. I can handle being a living and thankfully breathing example of cohort inversion, though. Being alive today, getting ready to celebrate my 33rd birthday, gives me opportunities to advocate for others who struggle to get their voices heard by health professionals and people in their everyday lives. It gives me a chance to fight for the next generation of people who walk the path I’ve walked, and perhaps to spare them some of the pain and suffering I’ve experienced. In some ways, my diagnosis is the best—if strangest—birthday gift I’ve ever received. Being diagnosed with CF doesn’t usually instill feelings of cheer and celebration for patients and their families, but after 33 years of being slowly killed by a disease with no name and no evidence basis for treatment, I feel like I’ve won the lottery. I’m also conscious that winning the lottery in many other ways earlier in life gave me a fighting chance of surviving long enough to receive a coherent clinical diagnosis. Ultimately, I’m writing this post today because my privileges in life enabled me to hang on long enough—with a combination of therapies and supports that have sometimes felt like throwing spaghetti against walls to see what sticks—to get some answers that make sense. This is in spite of decades of having good access to health care and associated social resources, as well as both the knowledge and tenacity to advocate for myself. After working in public health for 10 years, I know what has probably happened to many others like me. Most people with CF are white, yes. But not all of them grew up affluent or had parents with medical research backgrounds or many of the other social privileges I enjoyed. The question of “whose deaths matter” looms large here. The knowledge that I have survived where others have not brings a sense of responsibility, which led me to create an advocacy project (Write Where It Hurts) focusing on the work of scholars who have experienced severe illness and other forms of trauma. If I could say one thing to other members of the scientific community, it would be this: Nothing—not a sweat test, not a response to medication, not a physical exam—is more important than a person’s own experiences. In a truly person-centered health system, my clinicians would have asked a lot more questions a lot earlier. They would have told my parents part of the reason the sweat tests were inconclusive was that they couldn’t make me sweat because I was so hypotensive. They would have asked me if under circumstances where my face did sweat, the fluid was so salty it burned my skin. They would have asked me to describe my bowel movements in detail, told me it wasn’t usual to have clumps of undigested fat in your stool. They would have believed me when I said my kidneys hurt or that my calves were swollen. Maybe then I wouldn’t have sat in a hematologist’s office this past summer staring at the evidence of incipient kidney failure. Maybe now I wouldn’t be hoping against hope that the kidney symptoms are just evidence of vasculitis and nothing more. My life now is a series of maybes. There are companies working to change that. On happy accident, I’ve benefited from some of these therapies already. They just can’t take away the deeper wounds of being dismissed all those years, of feeling alone in my suffering, or of watching my body break down before my eyes. Developing new therapies for CF, whether the better understood homozygous type or the newly recognized heterozygous type, is not enough. Effective care for this disease is first and foremost about listening to people, and about finding the courage to affirm our voices. Lab tests are not going to save our lives and neither are drugs, because they cannot speak for us or fight for us. But if you are reading this post, you can, and I hope that you will. Alexandra “Xan” C.H. Nowakowski is a medical sociologist and public health program evaluator who studies patterns and disparities in how people age with complex chronic conditions. Dr. Nowakowski serves as the evaluator for the Florida Asthma Program, helps to lead FSU COM’s new Aging Research Institute, and volunteers with a variety of initiatives focused on health equity and patient advocacy. Along with their spouse Dr. J Sumerau, Dr. Nowakowski founded Write Where It Hurts, an advocacy project for scholars doing trauma informed research. Visit WWIH online at writewhereithurts.net.
News Article | October 27, 2016
Genomic startup 23andMe has scrapped plans to create cutting-edge next-generation gene-sequencing technology, saying its consumer base just isn't ready. CEO Anne Wojcicki said Wednesday during the Wall Street Journal's WSJ.D Live global technology conference in Laguna Beach, California, that while the company was creating the technology to help its customers learn even more about their DNA, it has decided to concentrate on its core operations of direct-to-consumer DNA testing kits. "Genetics is complicated," she said. "As a company, we are really focused on direct to consumer. Without a doubt we are a consumer product. We're not going through a physician. There is no other company out there that is direct to consumer." Three years ago, 23andMe was reprimanded by the Food and Drug Administration for giving out health information without involving a doctor. For more than a year, the FDA began letting the startup give some health information, such as warning of a genetic marker for cystic fibrosis, Wojcicki said. However, she admitted that Silicon Valley startups probably don't have a good understanding of how to deal with regulatory agencies. "You go to Silicon Valley because you want innovation, creativity," she said. "You don't go because you want regulatory expertise. Without a doubt, there was part of us that didn't necessarily understand how the regulatory environment worked." And while other companies are beginning to sell next-generation sequencing-based tests to consumers, Wojcicki said she doesn't see her company experiencing a setback but rather going through a valuable learning experience. "I don't see it as a setback at all. I see it as a company that really got to understand a new area and decided that we are going to focus and prioritize," she said. "Next-generation sequencing is without a doubt the hot shiny object, but what you're going to do with all of that information is an incredibly complicated area to get into... "It's a whole new world and a lot of people just don't understand the basics of genetic information and that's what I see are the huge priorities for the next few years is getting people to understand the basics."